MARCELLINO L ローマ大学(ラ, サピエンザ)・医学部, 教授
HAMASATO Shinji Kochi Medical School, Research Associate, 医学部, 助手 (60228533)
ARAKI Kiyonori Kochi Medical School, Research Associate, 医学部, 助手 (60151156)
TAKATA Masaru Kochi Medical School, Assistant Professor, 医学部, 講師 (80136374)
MARCELLINO Lucio Romano University of Rome "La Sapienza" Professor
MAFRCELLINO ルチオ ローマ大学(ラ, サピエンザ)・医学部, 教授
|Budget Amount *help
¥6,200,000 (Direct Cost : ¥6,200,000)
Fiscal Year 1996 : ¥3,100,000 (Direct Cost : ¥3,100,000)
Fiscal Year 1995 : ¥3,100,000 (Direct Cost : ¥3,100,000)
Since 1970, we have long been studying on cellular regulation of immune response to syngeneic tumors in mice. As the results, it was elecidated that cytotoxic T lymphocytes (CTL) which directly recognize and destroy a corresponding lumor are major effector cells in tumor regression, while when tumors grow in hosts, tumor specific suppressor T cells as well as some other non-specific suppressor cells such as macrophages which suppress induction of CTL activity, are strongly activated. However, ex-vivo induced and activated CTL against homologous tumor in spleen cells from the tumor bearing host by 5-7 day stimulation culture with the attenuated homologous tumor cells, are not usually suppressed by these suppressor mechanisms in vitro as well as in vivo of the tumor bearing host even after i.v.cell transfer of the in vitro activated CTL source.
On the bases of these experimental results, we devised a method how to induce and activate specific CTL directed to cancer cells in vitro in perip
heral lymphoid cells of the homologous cancer bearing patient by 7 day stimulation culture with the attenuated cancer cells, and established so called CTL therapy against cancer as an cancer specific immunotherapy by passively repeated i.v.cell transfer of the in vitro specifically activated CTL into the patient at 1986. We applied the CTL therapy for a breast cancer patient with lung and liver metastases and obtained successful results. once we presented this exciting result at the annual meeting of Japanese Cancer Association at 1987, NHK TV-news reported our result of CTL therapy internationally. Furthermore, the CTL therapy was applied for more various cancer patients in our lab and we obtained more good results and presented these results at the several international conferences such as the Congress of International Immunology, the International Cancer Conference, etc. Consequently, many medical scientists in various institutes and clinical departments of various universities wanted to collaborate with my group in the Department of Immunology, Kochi Medical School. Among these medical scientists, Professor Lucio R.Marcellino of the Department of Onco-surgery and Pathology, the University of Rome "La Sapienza" who was seriously aware of limitation of chemotherapy and radiation therapy against cancer, sincerely expressed his willing for tight collaboration with us for further development and application of the CTL therapy for cancer patients.
We started this project from these background. Therefore, the aim of this project is to develop and perform the CTL therapy for various cancer patients in both labs collaboratively and exchange our fundamental and clinical data for improvement of the CTL therapy. Less